我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
36
11 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
11
30.6%
已完成
19
52.8%
终止
3
8.3%
Unknown
2
5.6%
撤回
1
2.8%
暂无批准数据
- Merrimack Pharmaceuticals is focusing on advancing its oncology pipeline, particularly MM-398 for metastatic pancreatic cancer and MM-121 for various solid tumors. - A global phase III study of MM-398 is underway, evaluating its efficacy against 5-Fluorouracil and Leucovorin in patients who have failed Gemcitabine treatment. - MM-121, in partnership with Sanofi, is being tested in phase II studies across non-small cell lung cancer, HER2-negative breast cancer, and platinum-resistant ovarian cancers. - Merrimack's pipeline includes other clinical drug candidates like MM-111, MM-302, and MM-151, with plans to initiate a phase I trial for DX-929, an imaging diagnostic.
